Photo of Mark Swidler

Mark Swidler

Print ProfilePrint Profile


  • B.A., State University of New York at Binghamton


    Geriatric Nephrology and Renal Palliative Care
    The study of various aspects of aging and geriatric syndromes in the renal population is part of the developing field of geriatric nephrology which brings a geriatric perspective into the care of the elderly renal population with their high degree of frailty, complex pharmacology, cognitive and functional impairment, depression, and large symptom burden. Additionally, dialysis issues in the chronic outpatient and acute care settings have become more intricate from both a medical management and a bioethical standpoint. Utilizing palliative care concepts in order to optimize functionality, symptom control, and shared decision-making will allow patients and their families to better cope with the chronic progressive nature of CKD and help them navigate through end-of-life decisions. Integrating geriatrics and palliative medicine principals into the practice of nephrology will improve the management of these challenging patients. Establishing geriatric CKD data bases and studying the biology of chronic renal disease in the context of aging will help elucidate mechanisms of progression and allow earlier identification of patients at risk who need intervention.

    Dr. Swidler  is the Director of the Integrated Nephrology and Geriatric/Palliative Medicine Fellowship.

    T. Franklin Williams Scholar 2005


  • -
    Association of Subspecialty Professors Junior Development Award in Geriatric Nephrology
    American Society of Nephrology


Swidler M. Geriatric renal palliative care is coming of age. International urology and nephrology 2010 Sep; 42(3).

Bonventre JV, Swidler MA. Calcium dependency of prostaglandin E2 production in rat glomerular mesangial cells. Evidence that protein kinase C modulates the Ca2+-dependent activation of phospholipase A2. J Clin Invest 1988 Jul; 82(1): 168-76.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Swidler did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central